V
Vanessa Rousseau
Researcher at University of Toulouse
Publications - 102
Citations - 1944
Vanessa Rousseau is an academic researcher from University of Toulouse. The author has contributed to research in topics: Pharmacovigilance & Medicine. The author has an hindex of 16, co-authored 90 publications receiving 1423 citations. Previous affiliations of Vanessa Rousseau include Institut Gustave Roussy & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
David Malka,Pascale Cervera,Stéphanie Foulon,Tanja Trarbach,Christelle De La Fouchardiere,Eveline Boucher,Laetitia Fartoux,Sandrine Faivre,Jean-Frédéric Blanc,Frédéric Viret,Eric Assenat,Thomas Seufferlein,Thomas Herrmann,Julien Grenier,Pascal Hammel,Matthias M. Dollinger,Thierry André,Philipp Hahn,Volker Heinemann,Vanessa Rousseau,Michel Ducreux,Jean-Pierre Pignon,Dominique Wendum,Olivier Rosmorduc,Tim F. Greten +24 more
TL;DR: The addition of cetuximab to gemcitabine and oxaliplatin did not seem to enhance the activity of chemotherapy in patients with advanced biliary cancer, although it was well tolerated.
Journal ArticleDOI
ERCC1 Isoform Expression and DNA Repair in Non-Small-Cell Lung Cancer
Luc Friboulet,Ken A. Olaussen,Ken A. Olaussen,Jean Pierre Pignon,Frances A. Shepherd,Ming-Sound Tsao,Stephen L. Graziano,Robert A. Kratzke,Jean-Yves Douillard,Lesley Seymour,Robert Pirker,Martin Filipits,Fabrice Andre,Fabrice Andre,Eric Solary,Eric Solary,Florence Ponsonnailles,Florence Ponsonnailles,Angélique Robin,Angélique Robin,Annabelle Stoclin,Annabelle Stoclin,Nicolas Dorvault,Nicolas Dorvault,Frédéric Commo,Frédéric Commo,Julien Adam,Julien Adam,Elsa Vanhecke,Elsa Vanhecke,Patrick Saulnier,Jürgen Thomale,Thierry Le Chevalier,Thierry Le Chevalier,Ariane Dunant,Vanessa Rousseau,Gwénaël Le Teuff,Elisabeth Brambilla,Jean-Charles Soria,Jean-Charles Soria +39 more
TL;DR: It was found that none of the 16 antibodies could distinguish among the four ERCC1 protein isoforms, whereas only one isoform produced a protein that had full capacities for nucleotide excision repair and cisplatin resistance.
Journal ArticleDOI
MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer
Nermine S Kamal,Jean-Charles Soria,Jean Mendiboure,David Planchard,Ken A. Olaussen,Vanessa Rousseau,Helmut Popper,Robert Pirker,Pascale Bertrand,Ariane Dunant,Thierry Le Chevalier,Martin Filipits,Pierre Fouret +12 more
TL;DR: MSH2 expression is a borderline significant predictor of a long-term benefit from adjuvant cisplatin-based chemotherapy in patients with completely resected lung cancer.
Journal ArticleDOI
Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses
William E. Pierceall,Ken A. Olaussen,Ken A. Olaussen,Ken A. Olaussen,Vanessa Rousseau,Elisabeth Brambilla,K. M. Sprott,Fabrice Andre,Fabrice Andre,J.P. Pignon,T. Le Chevalier,R. Pirker,C. Jiang,Martin Filipits,Y. Chen,Jeffrey L. Kutok,David T. Weaver,B.E. Ward,Jeannette Soria +18 more
TL;DR: Predictive utility of DNA repair enzymes co-segregates with SCC histology, focusing their predictive value to this histological subclass of NSCLC.
Journal ArticleDOI
Serotonin Syndrome: Analysis of Cases Registered in the French Pharmacovigilance Database.
Delphine Abadie,Vanessa Rousseau,Sophie Logerot,Judith Cottin,Jean-Louis Montastruc,François Montastruc +5 more
TL;DR: This first study about SS based on a large pharmacovigilance database and published in English reveals not only the frequent involvement of antidepressants and tramadol, the importance of DDIs (both pharmacodynamic and pharmacokinetic), but also the significant risk of SS even with a single serotonergic drug used at normal dose.